Open AccessSafety and Immunogenicity of Trivalent Inactivated Influenza Vaccine in Infants
Author(s) -
Natasha Halasa,
Michael A. Gerber,
Qingxia Chen,
Peter F. Wright,
Kathryn M. Edwards
Publication year - 2008
Publication title -
the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1086/587643
Subject(s) - vaccination , medicine , titer , immunogenicity , influenza vaccine , hemagglutination assay , immunology , trivalent influenza vaccine , seroconversion , antibody titer , antibody , adverse effect , live attenuated influenza vaccine , virology , pediatrics
Trivalent inactivated influenza vaccine (TIV) is not licensed for use in infants <6 months old, the group with the highest influenza hospitalization rates among children.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom